Last year's digital health investment trends have left some startups feeling uneasy about their ability to raise capital in the new funding environment. Venture capitalists think companies that have a demonstrable return on investment and serve multiple stakeholders will probably have the easiest time securing capital, while point solutions and startups in crowded markets will face a tougher environment.
Don't miss your opportunity to experience the premier networking event in healthcare. Join us May 22-24, 2023 at the Ritz Carlton in Chicago and get access to exclusive networking opportunities, mingle with investors and cutting edge startups, Ask CIOs, and so much more.
Ciox recently partnered with Virginia-based non-profit health system Sentara Healthcare to pilot a tool that makes it easier for expectant mothers to access their health records. The fact that patients' pregnancy data get trapped in silos is problematic because providers can use that information to predict complications and intervene sooner.
Blue Shield of California's new health plan, Virtual Blue, gives members virtual access to primary care through Accolade and virtual access to specialty care through TeleMed2U. If needed, they can also receive in-person care through the payer's PPO network.
Smile Digital Health recently raised $30 million in Series B capital. The startup sells its health data fabric platform to providers, payers, digital health vendors and researchers. The platform gives customers the ability to store, search and evaluate patient information.
The Kaiser Family Foundation examined pre-pandemic data to determine what will happen to those disenrolled from Medicaid and CHIP once the continuous enrollment requirement ends March 31. The analysis found that 65% of those disenrolled went through a period of uninsurance.
This eBook highlights how contract research organizations are collaborating with technology developers, the role that digital therapeutics could play in clinical trials, how companies are thinking about clinical trial diversity and the challenges in using real-world evidence to replicate clinical trials.
No comments